

Rajender R Aparasu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8287384/publications.pdf>

Version: 2024-02-01

142
papers

3,391
citations

147801

31
h-index

182427

51
g-index

143
all docs

143
docs citations

143
times ranked

3776
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthcare Outcomes Associated with Beers' Criteria: A Systematic Review. <i>Annals of Pharmacotherapy</i> , 2007, 41, 438-448.	1.9	239
2	Inappropriate Prescribing for the Elderly: Beers Criteria-Based Review. <i>Annals of Pharmacotherapy</i> , 2000, 34, 338-346.	1.9	208
3	Psychotropic Prescription Use by Community-Dwelling Elderly in the United States. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 671-677.	2.6	121
4	Inappropriate Medication Prescribing for the Elderly by Office-Based Physicians. <i>Annals of Pharmacotherapy</i> , 1997, 31, 823-829.	1.9	109
5	Prescribing Potentially Inappropriate Psychotropic Medications to the Ambulatory Elderly. <i>Archives of Internal Medicine</i> , 2000, 160, 2825.	3.8	106
6	Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. <i>Drugs and Aging</i> , 2009, 26, 483-492.	2.7	97
7	Antipsychotic drug use among elderly nursing home residents in the United States. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 187-197.	3.0	93
8	Inappropriate prescribing for elderly outpatients. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 433-439.	1.0	76
9	The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. <i>Cancer</i> , 2019, 125, 1155-1162.	4.1	72
10	Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. <i>American Journal of Geriatric Pharmacotherapy</i> , 2004, 2, 102-111.	3.0	64
11	Prescribing of Psychotropics in the Elderly. <i>CNS Drugs</i> , 2002, 16, 99-109.	5.9	62
12	Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature. <i>Pharmacotherapy</i> , 2006, 26, 1307-1313.	2.6	61
13	Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. <i>Alzheimer's and Dementia</i> , 2012, 8, 437-444.	0.8	61
14	Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. <i>Current Medical Research and Opinion</i> , 2007, 23, 49-56.	1.9	57
15	Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents. <i>Psychiatric Services</i> , 2010, 61, 130-136.	2.0	56
16	Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 446-459.	3.0	55
17	Opioid-Induced Emesis Among Hospitalized Nonsurgical Patients. <i>Journal of Pain and Symptom Management</i> , 1999, 18, 280-288.	1.2	54
18	Clinically important potential drug-drug interactions in outpatient settings. <i>Research in Social and Administrative Pharmacy</i> , 2007, 3, 426-437.	3.0	50

#	ARTICLE	IF	CITATIONS
19	Prevalence and Predictors of Antidepressant Prescribing in Nursing Home Residents in the United States. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 109-119.	3.0	50
20	Risk factors for dementia in patients over 65 with diabetes. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 749-757.	2.7	49
21	U.S. National Trends in the Use of Antipsychotics During Office Visits, 1998–2002. <i>Annals of Clinical Psychiatry</i> , 2005, 17, 147-152.	0.6	48
22	Prevalence and Predictors of Anticholinergic Medication Use in Elderly Nursing Home Residents with Dementia. <i>Drugs and Aging</i> , 2010, 27, 987-997.	2.7	48
23	Application of machine learning in predicting hospital readmissions: a scoping review of the literature. <i>BMC Medical Research Methodology</i> , 2021, 21, 96.	3.1	46
24	Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 358-363.	3.0	45
25	A Comparison of Supervised Machine Learning Techniques for Predicting Short-Term In-Hospital Length of Stay among Diabetic Patients. , 2014, , .		44
26	Prevalence and Determinants of Anticholinergic Medication Use in Elderly Dementia Patients. <i>Drugs and Aging</i> , 2013, 30, 837-844.	2.7	42
27	Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case–Control Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 394-400.	2.6	41
28	Persistence of Stimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 139-148.	1.3	36
29	Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study. <i>Drugs and Aging</i> , 2015, 32, 379-389.	2.7	36
30	The Definition and Prevalence of Pediatric Psychotropic Polypharmacy. <i>Psychiatric Services</i> , 2011, 62, 1450-1455.	2.0	34
31	Risk of Falls and Fractures in Older Adults Using Atypical Antipsychotic Agents: A Propensity Score–Adjusted, Retrospective Cohort Study. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 83-94.	3.0	33
32	Prevalence and Predictors of Anticholinergic Agents in Elderly Outpatients with Dementia. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 434-441.	3.0	32
33	Psychotropic prescribing for the elderly in office-based practice. <i>Clinical Therapeutics</i> , 1998, 20, 603-616.	2.5	30
34	Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 198-204.	3.0	30
35	Risk of Falls and Fractures in Older Adults Using Antipsychotic Agents. <i>Drugs and Aging</i> , 2010, 27, 815-829.	2.7	29
36	Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1492-1497.	2.6	28

#	ARTICLE	IF	CITATIONS
37	The Impact of Medicare Part D on Psychotropic Utilization and Financial Burden for Community-Based Seniors. <i>Psychiatric Services</i> , 2008, 59, 1191-1197.	2.0	27
38	Risk of Death in Dual-eligible Nursing Home Residents Using Typical or Atypical Antipsychotic Agents. <i>Medical Care</i> , 2012, 50, 961-969.	2.4	26
39	Consideration of Aggressive and Strategic Approaches to Address Declining Enrollment in US Pharmacy Schools. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6959.	2.1	26
40	Extent of functional impairment in children and adolescents with depression. <i>Current Medical Research and Opinion</i> , 2010, 26, 2057-2064.	1.9	25
41	Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. <i>Psychiatric Services</i> , 2017, 68, 681-688.	2.0	25
42	Discharge medication complexity and 30-day heart failure readmissions. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 857-863.	3.0	25
43	Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. <i>Drugs and Aging</i> , 2012, 29, 807-817.	2.7	24
44	Potentially inappropriate anticholinergic medication use in older adults with dementia. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 603-612.	1.5	24
45	Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 485-495.	1.2	24
46	Risk of Cerebrovascular Adverse Events in Older Adults Using Antipsychotic Agents. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 689-698.	2.2	23
47	Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 423-432.	2.6	23
48	Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. <i>Current Medical Research and Opinion</i> , 2008, 24, 709-716.	1.9	22
49	Concurrent Use of Stimulants and Second-Generation Antipsychotics Among Children With ADHD Enrolled in Medicaid. <i>Psychiatric Services</i> , 2015, 66, 404-410.	2.0	22
50	Datapoints: Antipsychotic Prescribing Trends Among Youths, 1997-2002. <i>Psychiatric Services</i> , 2005, 56, 904-904.	2.0	21
51	Risk of Pneumonia in Elderly Nursing Home Residents Using Typical Versus Atypical Antipsychotics. <i>Annals of Pharmacotherapy</i> , 2013, 47, 464-474.	1.9	21
52	Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. <i>Drugs and Aging</i> , 2017, 34, 691-700.	2.7	21
53	Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 120-132.	3.0	20
54	Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 604-613.	3.0	20

#	ARTICLE	IF	CITATIONS
55	Concomitant antipsychotic prescribing in US outpatient settings. <i>Research in Social and Administrative Pharmacy</i> , 2009, 5, 234-241.	3.0	18
56	Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. <i>Psychiatric Services</i> , 2015, 66, 1333-1340.	2.0	18
57	Outcomes associated with <i>Clostridium difficile</i> infection in patients with chronic liver disease. <i>Epidemiology and Infection</i> , 2018, 146, 1101-1105.	2.1	18
58	Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 13-26.	3.0	17
59	Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 329-335.	3.0	16
60	Drug-related-injury visits to hospital emergency departments. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 1158-1161.	1.0	15
61	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 233-240.	1.9	15
62	Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 395-403.	3.0	15
63	Visits to Office-Based Physicians in the United States for Medication-Related Morbidity. <i>Journal of the American Pharmacists Association</i> , 1999, 39, 332-337.	0.5	14
64	Attitudinal Dimensions that Determine Pharmacists'™ Decisions to Support DTCA of Prescription Medication. <i>Drug Information Journal</i> , 2000, 34, 103-114.	0.5	14
65	Antipsychotic Use and Expenditure in the United States. <i>Psychiatric Services</i> , 2006, 57, 1693-1693.	2.0	14
66	Risk of Manic Switch Associated with Antidepressant Therapy in Pediatric Bipolar Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 551-561.	1.3	14
67	Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 349-358.	1.3	13
68	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 2084-2093.	2.6	13
69	The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. <i>Journal of Affective Disorders</i> , 2013, 150, 424-429.	4.1	12
70	Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2187-2199.	1.8	12
71	Risk of Hospitalization and Use of First- Versus Second-Generation Antipsychotics Among Nursing Home Residents. <i>Psychiatric Services</i> , 2014, 65, 781-788.	2.0	11
72	Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. <i>Drugs and Aging</i> , 2015, 32, 743-754.	2.7	11

#	ARTICLE	IF	CITATIONS
73	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. <i>Drugs and Aging</i> , 2016, 33, 755-763.	2.7	11
74	The association between geographic access to providers and the treatment quality of pediatric depression. <i>Journal of Affective Disorders</i> , 2019, 253, 162-170.	4.1	11
75	Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications. <i>Brain Sciences</i> , 2022, 12, 59.	2.3	11
76	Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 299-308.	1.9	10
77	Anticholinergic drugs and health-related quality of life in older adults with dementia. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 282-287.	1.5	10
78	Which risk-adjustment index performs better in predicting 30-day mortality? A systematic review and meta-analysis. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 292-299.	1.8	10
79	Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 678-686.	1.9	10
80	Hypertension management in outpatient visits by diabetic patients. <i>Research in Social and Administrative Pharmacy</i> , 2008, 4, 284-291.	3.0	9
81	Unmet prescription medication need in U.S. children. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 769-776.	1.5	9
82	Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. <i>Pharmacotherapy</i> , 2017, 37, 287-296.	2.6	9
83	Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. <i>Psychiatry Research</i> , 2019, 276, 151-159.	3.3	9
84	Documentation of asthma control and severity in pediatrics: analysis of national office-based visits. <i>Journal of Asthma</i> , 2020, 57, 205-216.	1.7	9
85	Anticholinergic medications and risk of dementia in older adults: Where are we now?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1251-1267.	2.4	9
86	Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 195-206.	1.4	8
87	Prevalence and predictors of human papillomavirus vaccination in adolescent girls. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, 52-58.	1.5	8
88	Prevalence of anticholinergic use among older home health patients. <i>Journal of Clinical Nursing</i> , 2013, 22, 285-288.	3.0	8
89	Predictors of Concomitant Use of Antipsychotics and Stimulants and Its Impact on Stimulant Persistence in Pediatric Attention Deficit Hyperactivity Disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 486-498.	0.9	8
90	Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 395-404.	1.9	8

#	ARTICLE	IF	CITATIONS
91	The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. <i>Substance Use and Misuse</i> , 2017, 52, 1266-1274.	1.4	8
92	Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. <i>Journal of Psychiatric Research</i> , 2019, 117, 116-121.	3.1	8
93	Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. <i>Child and Adolescent Mental Health</i> , 2020, 25, 28-35.	3.5	8
94	Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression. <i>Drug, Healthcare and Patient Safety</i> , 2020, Volume 12, 23-30.	2.5	8
95	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 684-696.	2.7	8
96	Visits to Hospital Outpatient Departments in the United States Due to Adverse Effects of Medications. <i>Hospital Pharmacy</i> , 2000, 35, 825-831.	1.0	7
97	Datapoints: Antipsychotic Utilization and Expenditure Trends Among Elderly Persons. <i>Psychiatric Services</i> , 2007, 58, 1400-1400.	2.0	7
98	Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis. <i>Research in Social and Administrative Pharmacy</i> , 2012, 8, 145-156.	3.0	7
99	Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. <i>Pharmacotherapy</i> , 2016, 36, 38-48.	2.6	7
100	Functional Status of Elderly Nursing Home Residents With Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 617-624.	2.8	7
101	Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. <i>Journal of Attention Disorders</i> , 2019, 23, 163-172.	2.6	7
102	Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 741-749.	0.9	7
103	Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1670-1676.	3.0	7
104	Pharmacotherapy with Atomoxetine for US Children and Adolescents. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 175-180.	0.6	6
105	Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 461-473.	1.4	6
106	Atypical antipsychotic prescribing in elderly patients with depression. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 645-652.	3.0	6
107	Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 29-38.	0.9	6
108	Psychotropic Medication Expenditures for Community-Dwelling Elderly Persons. <i>Psychiatric Services</i> , 2003, 54, 739-742.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Health care consequences of black-box warnings for antidepressants in the United States and Canada. <i>Research in Social and Administrative Pharmacy</i> , 2010, 6, 78-84.	3.0	5
110	Use of narcotic analgesics associated with increased falls and fractures in elderly patients with osteoarthritis. <i>Evidence-Based Medicine</i> , 2014, 19, 37-38.	0.6	5
111	Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. <i>Journal of Affective Disorders</i> , 2018, 235, 155-161.	4.1	5
112	Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102334.	2.0	5
113	Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1079-1088.	1.2	5
114	Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1300-1306.	2.5	5
115	Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. <i>Drugs and Aging</i> , 2021, 38, 593-602.	2.7	5
116	Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. <i>Pain Medicine</i> , 2021, 22, 2224-2234.	1.9	4
117	The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US. <i>Pharmacoeconomics - Open</i> , 2021, 5, 727-736.	1.8	4
118	Impact of geographic access to primary care providers on pediatric behavioral health screening. <i>Preventive Medicine</i> , 2021, 153, 106856.	3.4	4
119	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. <i>Drugs and Aging</i> , 2022, 39, 453-465.	2.7	4
120	Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. <i>Annals of Pharmacotherapy</i> , 2016, 50, 96-105.	1.9	3
121	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1303-1313.	1.9	3
122	Pharmacy Education In Indonesia. <i>Pharmacy Education</i> , 0, 21, 432-442.	0.6	3
123	Prescribing of disease modifying agents in older adults with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103308.	2.0	3
124	Datapoints: Psychotropic Drug Use Among Elderly Patients in Home Care in the United States. <i>Psychiatric Services</i> , 2012, 63, 6-6.	2.0	2
125	Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. <i>Drugs and Aging</i> , 2021, 38, 493-502.	2.7	2
126	Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104019.	2.0	2

#	ARTICLE	IF	CITATIONS
127	Path model for analyzing factors associated with salaries of Louisiana hospital pharmacists. American Journal of Health-System Pharmacy, 1996, 53, 1706-1708.	1.0	1
128	Pilot of a patient-centered pharmacy practice model. American Journal of Health-System Pharmacy, 2012, 69, 1860-1861.	1.0	1
129	Asthma Medication Prescribing Practices in Pediatric Office Visits. Clinical Pediatrics, 2019, 58, 395-405.	0.8	1
130	Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Advances in Therapy, 2020, 37, 3584-3605.	2.9	1
131	Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs and Aging, 2021, 38, 311-326.	2.7	1
132	Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy, 2021, 41, 440-450.	2.6	1
133	National surveys to evaluate prescribing practices: Methodological considerations. Research in Social and Administrative Pharmacy, 2021, , .	3.0	1
134	Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2022, 70, 820-830.	2.6	1
135	FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Multiple Sclerosis and Related Disorders, 2022, 60, 103703.	2.0	1
136	Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study. Drugs - Real World Outcomes, 2015, 2, 61-71.	1.6	0
137	FRAX tool underestimates the risk of osteoporotic fractures in mental disorders. Evidence-Based Mental Health, 2018, 21, 80-80.	4.5	0
138	Acetylcholinesterase Inhibitors: Start Low or Risk Going Slow?. Journal of the American Geriatrics Society, 2018, 66, 1663-1664.	2.6	0
139	Chemoprotective effect of metformin against HR+/HER2- breast cancer among women with type-2 diabetes.. Journal of Clinical Oncology, 2021, 39, 10518-10518.	1.6	0
140	Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100021.	1.0	0
141	The impact of concomitant use of tyrosine kinase inhibitors and proton pump inhibitors on survival in older adults with cancer.. Journal of Clinical Oncology, 2018, 36, e18732-e18732.	1.6	0
142	Use of national databases and surveys to evaluate prescribing patterns and medication use. , 2022, , 527-539.		0